BACKGROUND: This report from the Working Group on Stereotaktische Radiotherapie of the German Society of Radiation Oncology (Deutsche Gesellschaft für Radioonkologie, DEGRO) provides recommendations for the use of stereotactic radiosurgery (SRS) on patients with brain metastases. It considers existing international guidelines and details them where appropriate. RESULTS AND DISCUSSION: The main recommendations are: Patients with solid tumors except germ cell tumors and small-cell lung cancer with a life expectancy of more than 3 months suffering from a single brain metastasis of less than 3 cm in diameter should be considered for SRS. Especially when metastases are not amenable to surgery, are located in the brain stem, and have no mass effect, SRS should be offered to the patient. For multiple (two to four) metastases--all less than 2.5 cm in diameter--in patients with a life expectancy of more than 3 months, SRS should be used rather than whole-brain radiotherapy (WBRT). Adjuvant WBRT after SRS for both single and multiple (two to four) metastases increases local control and reduces the frequency of distant brain metastases, but does not prolong survival when compared with SRS and salvage treatment. As WBRT carries the risk of inducing neurocognitive damage, it seems reasonable to withhold WBRT for as long as possible. CONCLUSION: A single (marginal) dose of 20 Gy is a reasonable choice that balances the effect on the treated lesion (local control, partial remission) against the risk of late side effects (radionecrosis). Higher doses (22-25 Gy) may be used for smaller (< 1 cm) lesions, while a dose reduction to 18 Gy may be necessary for lesions greater than 2.5-3 cm. As the infiltration zone of the brain metastases is usually small, the GTV-CTV (gross tumor volume-clinical target volume) margin should be in the range of 0-1 mm. The CTV-PTV (planning target volume) margin depends on the treatment technique and should lie in the range of 0-2 mm. Distant brain recurrences fulfilling the aforementioned criteria can be treated with SRS irrespective of previous WBRT.
BACKGROUND: This report from the Working Group on Stereotaktische Radiotherapie of the German Society of Radiation Oncology (Deutsche Gesellschaft für Radioonkologie, DEGRO) provides recommendations for the use of stereotactic radiosurgery (SRS) on patients with brain metastases. It considers existing international guidelines and details them where appropriate. RESULTS AND DISCUSSION: The main recommendations are: Patients with solid tumors except germ cell tumors and small-cell lung cancer with a life expectancy of more than 3 months suffering from a single brain metastasis of less than 3 cm in diameter should be considered for SRS. Especially when metastases are not amenable to surgery, are located in the brain stem, and have no mass effect, SRS should be offered to the patient. For multiple (two to four) metastases--all less than 2.5 cm in diameter--in patients with a life expectancy of more than 3 months, SRS should be used rather than whole-brain radiotherapy (WBRT). Adjuvant WBRT after SRS for both single and multiple (two to four) metastases increases local control and reduces the frequency of distant brain metastases, but does not prolong survival when compared with SRS and salvage treatment. As WBRT carries the risk of inducing neurocognitive damage, it seems reasonable to withhold WBRT for as long as possible. CONCLUSION: A single (marginal) dose of 20 Gy is a reasonable choice that balances the effect on the treated lesion (local control, partial remission) against the risk of late side effects (radionecrosis). Higher doses (22-25 Gy) may be used for smaller (< 1 cm) lesions, while a dose reduction to 18 Gy may be necessary for lesions greater than 2.5-3 cm. As the infiltration zone of the brain metastases is usually small, the GTV-CTV (gross tumor volume-clinical target volume) margin should be in the range of 0-1 mm. The CTV-PTV (planning target volume) margin depends on the treatment technique and should lie in the range of 0-2 mm. Distant brain recurrences fulfilling the aforementioned criteria can be treated with SRS irrespective of previous WBRT.
Authors: John H Suh; Gregory M M Videtic; Amr M Aref; Isabelle Germano; Brian J Goldsmith; Joseph P Imperato; Karen J Marcus; Michael W McDermott; Mark W McDonald; Roy A Patchell; H Ian Robins; C Leland Rogers; Aaron H Wolfson; Franz J Wippold; Laurie E Gaspar Journal: Curr Probl Cancer Date: 2010 May-Jun Impact factor: 3.187
Authors: Harald Treuer; Martin Kocher; Moritz Hoevels; Stefan Hunsche; Klaus Luyken; Mohammad Maarouf; Jürgen Voges; Rolf-Peter Müller; Volker Sturm Journal: Radiother Oncol Date: 2006-09-26 Impact factor: 6.280
Authors: Brian J Blonigen; Ryan D Steinmetz; Linda Levin; Michael A Lamba; Ronald E Warnick; John C Breneman Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-23 Impact factor: 7.038
Authors: Steven N Kalkanis; Douglas Kondziolka; Laurie E Gaspar; Stuart H Burri; Anthony L Asher; Charles S Cobbs; Mario Ammirati; Paula D Robinson; David W Andrews; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Mark E Linskey Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130
Authors: Mario Ammirati; Charles S Cobbs; Mark E Linskey; Nina A Paleologos; Timothy C Ryken; Stuart H Burri; Anthony L Asher; Jay S Loeffler; Paula D Robinson; David W Andrews; Laurie E Gaspar; Douglas Kondziolka; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Roy A Patchell; Steven N Kalkanis Journal: J Neurooncol Date: 2009-12-03 Impact factor: 4.130
Authors: Harald Treuer; Moritz Hoevels; Klaus Luyken; Veerle Visser-Vandewalle; Jochen Wirths; Martin Kocher; Maximilian Ruge Journal: Strahlenther Onkol Date: 2015-10 Impact factor: 3.621
Authors: Marcel A Kamp; Philipp J Slotty; Jan F Cornelius; Hans-Jakob Steiger; Marion Rapp; Michael Sabel Journal: Neurosurg Rev Date: 2016-07-09 Impact factor: 3.042
Authors: Khaled Elsayad; Jan Kriz; Laith Samhouri; Uwe Haverkamp; Ronald Straeter; Walter Stummer; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2016-06-07 Impact factor: 3.621
Authors: Lotte Wilke; Nicolaus Andratschke; Oliver Blanck; Thomas B Brunner; Stephanie E Combs; Anca-Ligia Grosu; Christos Moustakis; Daniela Schmitt; Wolfgang W Baus; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2019-01-16 Impact factor: 3.621
Authors: Johannes Knipps; Igor Fischer; Lisa M Neumann; Marion Rapp; Maxine Dibué-Adjei; Christiane Freiin von Saß; Jan-Malte Placke; Hendrik-Jan Mijderwijk; Hans-Jakob Steiger; Michael Sabel; Jan-Frederick Cornelius; Marcel A Kamp Journal: Clin Exp Metastasis Date: 2019-08-02 Impact factor: 5.150